Dr. Hyder Khoja is hoping to use psychedelics to treat patients in comas in a bid to stimulate them back into consciousness.
Psychedelics have the potential to treat various mental conditions, with more uses still being discovered. There are roughly 59 clinical trials registered around the world that plan on using psilocybin to manage mental health conditions. While a majority of these clinical trials are focusing on mental ailments such as OCD, anxiety and depression, Khoja intends to use these powerful substances to jump-start consciousness in unresponsive patients in comas.
Khoja, who received his molecular biology and genetic engineering PhD in 2003, is now working on developing a coma resurrection therapy using compounds such as DMT, LSD and psilocybin through his company Transcendent Therapeutics.
Various head injuries, from strokes to road accidents, can result in patients being in comas. While a majority of patients in comas usually come out of their comas, some stay unconscious indefinitely. Khoja states that any patient who is in a coma is termed medically dead because their brain is dead. Medically, this is termed as brain death.
However, Khoja refutes this, explaining that as a scientist, using the term brain death means that the brain is disconnected from the body. If the brain was dead, it wouldn’t be able to communicate with an individual’s nerves, veins and heart. The heart is still pumping in a patient who is in a coma, which he says he does not consider as total brain death.
Khoja goes on to explain that traumatic brain injuries, which are often the cause of comas, may damage the neural circuits in the brain that are responsible for allowing an individual to become conscious. This, he says, may be what keeps coma patients in this state of unconsciousness, which is where psychedelics come in. Khoja asserts that psychedelics may help revive these connections in the brain.
Khoja was inspired to look into psychedelics as a treatment for coma patients after his mother fell into a coma following complications from brain surgery. She’d woken up there weeks after the operation, which he noted was for a short while, because right after that, she slipped into a comatose state for two years.
While there are still no treatments for patients in comas, Khoja remains hopeful and focused on the possible effect that his therapy could have on patients in comas as well as their families.
Speaking of looking at psychedelics progressively, XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a company headquartered in British Columbia has focused all its R&D efforts on psychedelic medicines, sublingual plus transdermal drugs, as well as diagnostics for infectious diseases.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.